Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

P3 Health Partners (PIII) Gains from Sales and Divestitures (2019 - 2022)

Historic Gains from Sales and Divestitures for P3 Health Partners (PIII) over the last 4 years, with Q4 2022 value amounting to $5.0 million.

  • P3 Health Partners' Gains from Sales and Divestitures changed N/A to $5.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $5.0 million, marking a year-over-year change of. This contributed to the annual value of $5.0 million for FY2022, which is N/A changed from last year.
  • Latest data reveals that P3 Health Partners reported Gains from Sales and Divestitures of $5.0 million as of Q4 2022.
  • P3 Health Partners' Gains from Sales and Divestitures' 5-year high stood at $5.0 million during Q4 2022, with a 5-year trough of $443750.0 in Q4 2020.
  • Its 4-year average for Gains from Sales and Divestitures is $2.5 million, with a median of $660417.0 in 2021.
  • The largest annual percentage gain for P3 Health Partners' Gains from Sales and Divestitures in the last 5 years was 2993.42% (2020), contrasted with its biggest fall of 2993.42% (2020).
  • P3 Health Partners' Gains from Sales and Divestitures (Quarter) stood at $633333.0 in 2019, then dropped by 29.93% to $443750.0 in 2020, then surged by 48.83% to $660417.0 in 2021, then surged by 662.85% to $5.0 million in 2022.
  • Its Gains from Sales and Divestitures was $5.0 million in Q4 2022, compared to $5.0 million in Q3 2022 and $4.9 million in Q2 2022.